Enasidenib is a 1,3,5-triazine that is substituted by (2-hydroxy-2-methylpropyl)nitrilo, 6-(trifluoromethyl)pyridin-2-yl and [2-(trifluoromethyl)pyridin-4-yl]nitrilo groups at positions 2,4 and 6, respectively. It is an isocitrate dehydrogenase-2 (IDH2) inhibitor which has received approval for the treatment of adults with relapsed or refractory acute myeloid leukaemia (AML). Among its listed roles, it functions as a antineoplastic agent and an EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor. It is an aminopyridine, an organofluorine compound, a secondary amino compound, a tertiary alcohol, a member of 1,3,5-triazines and an aromatic amine. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include enasidenibum and Enasidenib. Its PubChem CID is 89683805.
Enasidenib
| CAS No | 1446502-11-9 |
|---|---|
| Molecular Formula | C19H17F6N7O |
| Molecular Weight | 473.4 g/mol |
| Synonyms | 2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Enasidenib is a 1,3,5-triazine that is substituted by (2-hydroxy-2-methylpropyl)nitrilo, 6-(trifluoromethyl)pyridin-2-yl and [2-(trifluoromethyl)pyridin-4-yl]nitrilo groups at positions 2,4 and 6, respectively.
The listed CAS number is 1446502-11-9.
The listed molecular formula is C19H17F6N7O.
The listed molecular weight is 473.4 g/mol.
2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol.
The source lists enasidenibum and Enasidenib.